Richard Pizzi of Healthcare IT News reports:
Perlegen Sciences, Inc., a company exploring the clinical application of genetic research, plans to collaborate with an undisclosed electronic medical records vendor to identify and develop genetic markers that predict how patients are likely to respond to specific medical treatments.
Under the terms of the agreement, Perlegen, based in Mountain View, Calif. , will have exclusive access to the EMR vendor’s database of U.S. records for the purpose of assessing and selecting patients from whom appropriate genetic samples could be collected.The EMR provider will earn subscription and program fees, as well as “significant” participation in milestone payments tied to the successful launch of new diagnostic tests resulting from the collaboration.
[…]
Perlegen officials say each patient’s privacy rights will be protected.
The firm says it will work with the selected patient’s individual care provider to obtain DNA in a HIPAA-compliant, IRB-approved manner. Company officials say they won’t have access to patient identities, but instead will receive de-identified patient records, which can be re-identified only by participating healthcare institutions.
Once re-identified, participating patients and physicians will receive financial compensation for providing samples for further analysis.
[…]
Full story – Healthcare IT News